Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa

Experience from western Kenya

Kara Wools-Kaloustian, Silvester Kimaiyo, Lameck Diero, Abraham Siika, John Sidle, Constantin Yiannoutsos, Beverly Musick, Robert Einterz, Kenneth Fife, William M. Tierney

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Objectives: To determine the clinical and immunological outcomes of a cohort of HIV-infected patients receiving antiretroviral therapy. Design: Retrospective study of prospectively collected data from consecutively enrolled adult HIV-infected patients in eight HIV clinics in western Kenya. Methods: CD4 cell counts, weight, mortality, loss to follow-up and adherence to antiretroviral therapy were collected for the 2059 HIV-positive non-pregnant adult patients treated with antiretroviral drugs between November 2001 and February 2005. Results: Median duration of follow-up after initiation of antiretroviral therapy was 40 weeks (95% confidence interval, 38-43); 111 patients (5.4%) were documented as deceased and 505 (24.5%) were lost to follow-up. Among 1766 (86%) evaluated for adherence to their antiretroviral regimen, 78% reported perfect adherence at every visit. Although patients with and without perfect adherence gained weight, patients with less than perfect adherence gained 1.04 kg less weight than those reporting perfect adherence (P = 0.059). CD4 cell counts increased by a mean of 109 cells/μl during the first 6 weeks of therapy and increased more slowly thereafter, resulting in overall CD4 cell count increases of 160, 225 and 297 cells/μl at 12, 24, and 36 months respectively. At 1 year, a mean increase of 170 cells/μl was seen among patients reporting perfect adherence compared with 123 cells/μl among those reporting some missed doses (P < 0.001). Conclusions: Antiretroviral treatment of adult Kenyans in this cohort resulted in significant and persistent clinical and immunological benefit. These findings document the viability and effectiveness of large-scale HIV treatment initiatives in resource-limited settings.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalAIDS
Volume20
Issue number1
StatePublished - Jan 2006

Fingerprint

Africa South of the Sahara
Kenya
HIV
CD4 Lymphocyte Count
Therapeutics
Weights and Measures
Lost to Follow-Up
Weight Loss
Retrospective Studies
Confidence Intervals
Mortality
Pharmaceutical Preparations

Keywords

  • AIDS
  • Antiretroviral therapy
  • Computerized medical records system
  • HIV
  • Sub-Saharan Africa

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa : Experience from western Kenya. / Wools-Kaloustian, Kara; Kimaiyo, Silvester; Diero, Lameck; Siika, Abraham; Sidle, John; Yiannoutsos, Constantin; Musick, Beverly; Einterz, Robert; Fife, Kenneth; Tierney, William M.

In: AIDS, Vol. 20, No. 1, 01.2006, p. 41-48.

Research output: Contribution to journalArticle

@article{c8f8967a0ce848bea60c020590c6dd2d,
title = "Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya",
abstract = "Objectives: To determine the clinical and immunological outcomes of a cohort of HIV-infected patients receiving antiretroviral therapy. Design: Retrospective study of prospectively collected data from consecutively enrolled adult HIV-infected patients in eight HIV clinics in western Kenya. Methods: CD4 cell counts, weight, mortality, loss to follow-up and adherence to antiretroviral therapy were collected for the 2059 HIV-positive non-pregnant adult patients treated with antiretroviral drugs between November 2001 and February 2005. Results: Median duration of follow-up after initiation of antiretroviral therapy was 40 weeks (95{\%} confidence interval, 38-43); 111 patients (5.4{\%}) were documented as deceased and 505 (24.5{\%}) were lost to follow-up. Among 1766 (86{\%}) evaluated for adherence to their antiretroviral regimen, 78{\%} reported perfect adherence at every visit. Although patients with and without perfect adherence gained weight, patients with less than perfect adherence gained 1.04 kg less weight than those reporting perfect adherence (P = 0.059). CD4 cell counts increased by a mean of 109 cells/μl during the first 6 weeks of therapy and increased more slowly thereafter, resulting in overall CD4 cell count increases of 160, 225 and 297 cells/μl at 12, 24, and 36 months respectively. At 1 year, a mean increase of 170 cells/μl was seen among patients reporting perfect adherence compared with 123 cells/μl among those reporting some missed doses (P < 0.001). Conclusions: Antiretroviral treatment of adult Kenyans in this cohort resulted in significant and persistent clinical and immunological benefit. These findings document the viability and effectiveness of large-scale HIV treatment initiatives in resource-limited settings.",
keywords = "AIDS, Antiretroviral therapy, Computerized medical records system, HIV, Sub-Saharan Africa",
author = "Kara Wools-Kaloustian and Silvester Kimaiyo and Lameck Diero and Abraham Siika and John Sidle and Constantin Yiannoutsos and Beverly Musick and Robert Einterz and Kenneth Fife and Tierney, {William M.}",
year = "2006",
month = "1",
language = "English",
volume = "20",
pages = "41--48",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa

T2 - Experience from western Kenya

AU - Wools-Kaloustian, Kara

AU - Kimaiyo, Silvester

AU - Diero, Lameck

AU - Siika, Abraham

AU - Sidle, John

AU - Yiannoutsos, Constantin

AU - Musick, Beverly

AU - Einterz, Robert

AU - Fife, Kenneth

AU - Tierney, William M.

PY - 2006/1

Y1 - 2006/1

N2 - Objectives: To determine the clinical and immunological outcomes of a cohort of HIV-infected patients receiving antiretroviral therapy. Design: Retrospective study of prospectively collected data from consecutively enrolled adult HIV-infected patients in eight HIV clinics in western Kenya. Methods: CD4 cell counts, weight, mortality, loss to follow-up and adherence to antiretroviral therapy were collected for the 2059 HIV-positive non-pregnant adult patients treated with antiretroviral drugs between November 2001 and February 2005. Results: Median duration of follow-up after initiation of antiretroviral therapy was 40 weeks (95% confidence interval, 38-43); 111 patients (5.4%) were documented as deceased and 505 (24.5%) were lost to follow-up. Among 1766 (86%) evaluated for adherence to their antiretroviral regimen, 78% reported perfect adherence at every visit. Although patients with and without perfect adherence gained weight, patients with less than perfect adherence gained 1.04 kg less weight than those reporting perfect adherence (P = 0.059). CD4 cell counts increased by a mean of 109 cells/μl during the first 6 weeks of therapy and increased more slowly thereafter, resulting in overall CD4 cell count increases of 160, 225 and 297 cells/μl at 12, 24, and 36 months respectively. At 1 year, a mean increase of 170 cells/μl was seen among patients reporting perfect adherence compared with 123 cells/μl among those reporting some missed doses (P < 0.001). Conclusions: Antiretroviral treatment of adult Kenyans in this cohort resulted in significant and persistent clinical and immunological benefit. These findings document the viability and effectiveness of large-scale HIV treatment initiatives in resource-limited settings.

AB - Objectives: To determine the clinical and immunological outcomes of a cohort of HIV-infected patients receiving antiretroviral therapy. Design: Retrospective study of prospectively collected data from consecutively enrolled adult HIV-infected patients in eight HIV clinics in western Kenya. Methods: CD4 cell counts, weight, mortality, loss to follow-up and adherence to antiretroviral therapy were collected for the 2059 HIV-positive non-pregnant adult patients treated with antiretroviral drugs between November 2001 and February 2005. Results: Median duration of follow-up after initiation of antiretroviral therapy was 40 weeks (95% confidence interval, 38-43); 111 patients (5.4%) were documented as deceased and 505 (24.5%) were lost to follow-up. Among 1766 (86%) evaluated for adherence to their antiretroviral regimen, 78% reported perfect adherence at every visit. Although patients with and without perfect adherence gained weight, patients with less than perfect adherence gained 1.04 kg less weight than those reporting perfect adherence (P = 0.059). CD4 cell counts increased by a mean of 109 cells/μl during the first 6 weeks of therapy and increased more slowly thereafter, resulting in overall CD4 cell count increases of 160, 225 and 297 cells/μl at 12, 24, and 36 months respectively. At 1 year, a mean increase of 170 cells/μl was seen among patients reporting perfect adherence compared with 123 cells/μl among those reporting some missed doses (P < 0.001). Conclusions: Antiretroviral treatment of adult Kenyans in this cohort resulted in significant and persistent clinical and immunological benefit. These findings document the viability and effectiveness of large-scale HIV treatment initiatives in resource-limited settings.

KW - AIDS

KW - Antiretroviral therapy

KW - Computerized medical records system

KW - HIV

KW - Sub-Saharan Africa

UR - http://www.scopus.com/inward/record.url?scp=29144530598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144530598&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 41

EP - 48

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 1

ER -